Metformin IPF Clinical Trial Study NCT07520110
Summary
The National Institutes of Health's ClinicalTrials.gov registry has registered a new interventional clinical trial (NCT07520110) titled 'Metformin IPF Clinical Trial Study.' The trial is investigating metformin as a potential treatment for idiopathic pulmonary fibrosis (IPF). No regulatory obligations, compliance deadlines, or penalties are associated with this registry listing.
What changed
This document registers a new clinical trial (NCT07520110) on ClinicalTrials.gov. The trial studies metformin for the treatment of idiopathic pulmonary fibrosis (IPF). ClinicalTrials.gov listings are informational registry entries and do not create compliance obligations.
Affected parties including clinical investigators, trial sponsors, and healthcare providers may reference this listing for trial participation opportunities or regulatory documentation purposes. The registry entry serves as a public record of ongoing research but does not impose regulatory requirements on covered entities.
What to do next
- Monitor ClinicalTrials.gov for updates to NCT07520110
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.